drugset / Trial / NCT06053853
Post Marketing Surveillance of Diphtheria Antitoxin (DAT)
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety profile of Diphtheria Antitoxin
Timeline
- Start
- 2023-01-31
- Primary completion
- 2023-05-13
- Completion
- 2023-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 20000 iu | Intravenous |
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 40000 iu | Intravenous |
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 60000 iu | Intravenous |
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 80000 iu | Intravenous |
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 100000 iu | Intravenous |
| Subject | Diphtheria Antitoxin | Protein / enzyme biologic | 120000 iu | Intravenous |
Indications
No indication recorded.